Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

NCT00866138 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AB Science